Development of a core outcome set for clinical trials in rosacea: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey
Authors:
- Sanjana IyengarSISanjana Iyengar
- Paula R. WilliamsonPWPaula R. Williamson
- Jochen SchmittJSJochen Schmitt
- Lena JohannsenLJLena Johannsen
- Ian A. MaherIMIan A. Maher
- Joseph F. SobankoJSJoseph F. Sobanko
- Todd V. CarteeTCTodd V. Cartee
- Daniel SchlessingerDSDaniel Schlessinger
- Emily PoonEPEmily Poon
- Murad AlamMAMurad Alam
Open Access
- 1 September 2016
- journal article
- review article
- Published by Springer Nature in Trials
- Vol. 17 (1) , 1-6
Abstract
Rosacea is a chronic inflammatory disorder affecting millions of individuals worldwide. Diagnosis is based on signs and symptoms with management and treatment aimed to suppress inflammatory lesions, erythema, and telangiectasia. While many clinical trials of rosacea exist, the lack of consensus in outcome reporting across all trials poses a concern. Proper evaluation and comparison of treatment modalities is challenging. In order to address the inconsistencies present, this project aims to determine a core set of outcomes which should be evaluated in all clinical trials of rosacea. This project will utilize a methodology similar to previous core outcome set research. A long list of outcomes will be extracted over four phases: (1) systematic literature review, (2) patient interviews, (3) other published sources, and (4) stakeholder involvement. Potential outcomes will be examined by the Steering Committee to provide further insight. The Delphi process will then be performed to prioritize and condense the list of outcomes generated. Two homogenous groups of physicians and patients will participate in two consecutive rounds of Delphi surveys. A consensus meeting, composed of physicians, patients, and stakeholders, will be conducted after the Delphi exercise to further select outcomes, taking into account participant scores. By the end of the meeting, members will vote and decide on a final recommended set of core outcomes. For the duration of the study, we will be in collaboration with both the Core Outcome Measures in Effectiveness Trials (COMET) and Cochrane Skin Group - Core Outcome Set Initiative (CSG-COUSIN). This study aims to develop a core outcome set to guide assessment in clinical trials of rosacea. The end-goal is to improve the reliability and consistency of outcome reporting, thereby allowing sufficient evaluation of treatment effectiveness and patient satisfaction.Keywords
Funding Information
- Merz Center for Quality and Outcomes Resesarch in Dermatologic Surgery
- IMPROVED Group
This publication has 20 references indexed in Scilit:
- Clustering of autoimmune diseases in patients with rosaceaJournal of the American Academy of Dermatology, 2016
- Rosacea in Patients with Ulcerative Colitis and Crohnʼs DiseaseInflammatory Bowel Diseases, 2016
- New and Emerging Treatments for RosaceaAmerican Journal of Clinical Dermatology, 2015
- Rosacea associated with increased risk of some cancersThe Lancet Oncology, 2015
- Rosacea and cardiovascular disease: Is there an association?Journal of the American Academy of Dermatology, 2015
- Interventions for rosaceaCochrane Database of Systematic Reviews, 2015
- Reliability of Clinician Erythema Assessment grading scaleJournal of the American Academy of Dermatology, 2014
- Rosacea: Current state of epidemiologyJournal of the American Academy of Dermatology, 2013
- An observational cross-sectional survey of rosacea: clinical associations and progression between subtypesBritish Journal of Dermatology, 2013
- Rosacea and its management: an overviewJournal of the European Academy of Dermatology and Venereology, 2005